Eli Lilly and Company (NYSE: LLY), a United States-based pharmaceutical company, announced on Monday that the company is collaborating with International Agencies (Bangladesh) Ltd. (IABL).
Under the collaboration, Eli Lilly is to provide its active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) Ltd in an effort to raise patient access and improve affordability for high-quality insulin for around one million people living with diabetes in Bangladesh by 2030.
IABL is formulating, filling and finishing human insulin vials and cartridges under its own trademark and brand name by 2025. The IABL-developed insulin is being exclusively developed for the Bangladesh market.
Ilya Yuffa, Lilly International president, said, 'Lilly is committed to addressing the critical gaps in access to essential medicines for people living with diabetes in low- and middle-income countries. Through collaborations like this one with IABL, we are working to reduce barriers to access and ensure ongoing production and uninterrupted supply of insulin so that a greater number of patients can live healthier lives.'
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
AstraZeneca increases dividend by 7%
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
Wolters Kluwer enhances Clinical GenAI leadership with AI Labs powered by UpToDate
Amgen announces share dividend for Q2 2024
Virbac expands presence in Japan with Sasaeah acquisition
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva